India, Nov. 11 -- Wednesday, Braveheart Bio, Inc. (BRVE) reported third-quarter 2026 financial results and provided updates on its clinical development programs for BHB-1893, an investigational treatment for hypertrophic cardiomyopathy (HCM).
The company highlighted 52-week data from its Phase 2 study presented at the 2026 American Heart Association (AHA) Scientific Sessions, showing continued improvements in exercise capacity and health status among patients with obstructive HCM (oHCM).
Company Profile
Braveheart Bio is a clinical-stage biopharmaceutical company developing next-generation therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead candidate, BHB-1893, is being evaluated in both obstruct...